Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
...
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
- Associated Therapies
- -
Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 60
- Registration Number
- NCT00381368
- Locations
- 🇫🇮
Dept of Oncology, Helsinki University Central Hospital, Helsinki, Finland
🇫🇮Dept of Oncology, Tampere University Hospital, Tampere, Finland
🇫🇮Dept of Oncology, Oulu University Hospital, Oulu, Finland
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00327990
- Locations
- 🇳🇱
GSK Investigational Site, Zaandam, Netherlands
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
- Conditions
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00301886
Study in Elderly Patients With Early Breast Cancer (ICE)
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 1500
- Registration Number
- NCT00196859
- Locations
- 🇩🇪
Prof. Dr. med. Ulrike Nitz, Mönchengladbach, Nordrhein-Westfalen, Germany
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00148915
- Locations
- 🇺🇸
GSK Investigational Site, Duncansville, Pennsylvania, United States
Study of Investigational Drug in Osteoporosis (MK-0217-908)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 203
- Registration Number
- NCT00092053
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.